Drug intelligence / Profile preview

HL-7037

Development stage
Preclinical
Lead developer
Highslab Therapeutics
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

HL-7037 is a novel cyclic peptide radiopharmaceutical candidate designed to target glypican-3 (GPC3), which is highly upregulated in hepatocellular carcinoma (HCC) but has limited expression in healthy tissues. Developed by HighsLab Therapeutics, HL-7037 is designed to achieve selective GPC3 binding, tumor-specific uptake, and long-term tumor retention. It can be chelated with radiometal isotopes such as Gallium-68 (68Ga) for positron emission tomography (PET) imaging, or Lutetium-177 (177Lu) and Actinium-225 (225Ac) for targeted radionuclide therapy. Preclinical studies in HepG2 tumor-bearing mouse models have demonstrated high tumor-specific uptake and significant tumor growth inhibition.

02

Identity

Drug type
Peptides
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
hepatocellular carcinoma (HCC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
61
Drugs in the lead indication
966

Lead indication: hepatocellular carcinoma (HCC)

Most advanced in the lead indication

  1. ADC 3Approved
  2. atezolizumabApproved
  3. bevacizumabApproved
  4. cabozantinibApproved
  5. durvalumabApproved

Beyond the preview

Go deeper on HL-7037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL-7037.

Work on HL-7037? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call